Global Pharmaceutical Continuous Manufacturing Market

Pharmaceutical Continuous Manufacturing Market is expected to reach USD 1586.13 million by 2030, with a CAGR of 13 % between 2024 and 2030

Pharmaceutical Continuous Manufacturing Market Overview:

The research gives a comprehensive perspective of the market by combining qualitative and quantitative data. It examines the global Pharmaceutical Continuous Manufacturing Market and provides forecasts for the key segments. It also includes market size and forecast estimates for five key regions: North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America, for the years 2024 to 2030. The Pharmaceutical Continuous Manufacturing Market is further split into countries and markets within each location.To know about the Research Methodology :- Request Free Sample Report

Pharmaceutical Continuous Manufacturing Market Dynamics

The pharmaceutical continuous manufacturing market is expected to grow due to the rising scarcity of medications, and the benefits provided by the continuous manufacturing method are likely to drive the market. Additionally, emerging trends such as increased use of continuous production in pharmaceuticals are expected to drive growth during the forecast period.

Increasing Medicine Shortage is driving the Pharmaceutical Continuous Manufacturing Market:

Essential medications and pharmaceuticals are getting scarcer across the world. The growing shortfall places a strain on healthcare systems, incurring additional expenditures and putting patients' health at risk. Patients in need of medications are not receiving enough dosages owing to medication shortages. According to WHO Drug Information 2016, low, medium, and high-income nations have experienced shortages of important medications. Medicine shortages endanger patient health by causing non-treatment, under-treatment, and possibly medication mistakes caused by attempts to substitute missing medications.

The Significant Benefits of Continuous Process Manufacturing to Drive the Market

Continuous manufacturing is a high-level production strategy that has the potential to increase medicine quality and consistency while lowering costs. This production line is handled in a continuous stream, with manufacturing measures incorporated from start to end. Because of novel advancements in continuous manufacturing frameworks and support from administrative experts for the selection of continuous manufacturing frameworks, the pharmaceutical continuous manufacturing market is expected to see critical development throughout the forecast time frame. Nonetheless, the higher cost of pharmaceutical continuous manufacturing frameworks is impeding the pharmaceutical continuous manufacturing market.

Pharmaceutical Continuous Manufacturing Market Segment Analysis:

By Therapeutics Type, with the rising change in focus from batch processing to continuous production for drug development, small molecules dominated the market with a share of 75.7 % in 2023. This transformation is being driven primarily by commercial benefits such as decreased equipment size, cost-effectiveness, reduced time consumption, and a faster final product launch.
A comparable transformation is taking place in big molecule manufacture. Technological developments in single-use technologies and completely integrated control systems, as well as optimization in upstream and downstream processing, are expected to favorably benefit the biopharmaceutical continuous manufacturing segment's growth.

By Application, Thanks to the high percentage of drug developers that use this technology for drug production, finished-product manufacturing will account for 53.9 % of the market in 2023. As a consequence of the introduction of new goods and services by various companies, the use of continuous manufacturing processes for drug products is expected to grow in the future years, contributing to overall market growth.

Continuous manufacturing of active pharmaceutical ingredients (API) is becoming more common in the pharmaceutical industry since it is more cost-effective and time-consuming. A vast number of companies utilise this strategy to establish APIs all around the world. One of these companies is Pfizer, which uses a mixed approach to continuous API manufacture.

Pharmaceutical Continuous Manufacturing Market Regional Insight

In 2023, North America had the highest revenue share of 33.8 %. The growing number of end-users in North American countries that have embraced or plan to employ CM technology has led to the region's highest share of the market. Therefore, regulatory agencies are crucial in encouraging revenue growth in this region.

The Asia Pacific, driven by China and Japan, is expected to grow at the quickest CAGR throughout the forecast period. The region's rapidly developing CMO and biopharmaceutical sectors are expected to boost revenue growth. Additionally, multinational businesses are increasing their corporate footprints in this region, seeing it as a promising source of revenue in the pharmaceutical and biotechnology industries.

Report Objectives:

Landscape analysis of the Pharmaceutical Continuous Manufacturing Market
competitive benchmarking
Past and current status of the industry with the forecasted market size and trends
Evaluation of potential key players that include market leaders, followers, and new entrants
Technology trends
The potential impact of micro-economic factors on the market
External and Internal factors affecting the market have been analyzed

The report also helps in understanding the Market dynamics, and structure by analyzing the market segments to project the Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Market make the report investor’s guide.

Pharmaceutical Continuous Manufacturing Market Scope: Inquire before buying

Pharmaceutical Continuous Manufacturing Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)

Pharmaceutical Continuous Manufacturing Market, Key Players

1. Thermo Fisher Scientific, Inc.
2. Pall Corporation
3. Applikon Biotechnology
4. Sartorius Stedim Biotech
5. GEA Group Aktiengesellschaft
6. Corning Incorporated
7. Merck KGaA
8. Glatt GmbHh
9. Repligen Corporation
10. Eppendorf AG
11. Electrolab Biotech Ltd.
12. Solesis Medical
13. Scott Equipment Company
14. L.B. Bohle
15. LONZA

Frequently Asked Questions

1. What is the projected market size & growth rate of the Pharmaceutical Continuous Manufacturing Market?
Ans- The Pharmaceutical Continuous Manufacturing Market was valued at USD 674.20 million in 2023 and is projected to reach USD 1586.13 million by 2030, growing at a CAGR of 13 % during the forecast period.

2. What are the key driving factors for the growth of the Market?
Ans- Increasing Medicine Shortage is driving the Market.

3. Which Region accounted for the largest Pharmaceutical Continuous Manufacturing Market share?

Ans- In 2023, North America had the highest revenue share of 33.8 %.

4. What makes the North America a Lucrative Market for Pharmaceutical Continuous Manufacturing Market?
Ans- The growing number of end-users in North American countries that have embraced or plan to employ CM technology has led to the region's highest share of the market.

5. What are the top players operating in the Pharmaceutical Continuous Manufacturing Market?
Ans- Thermo Fisher Scientific, Inc., Pall Corporation, Applikon Biotechnology, Sartorius Stedim Biotech, GEA Group Aktiengesellschaft., Corning Incorporated